CO2017006308A2 - Derivados de glucagón - Google Patents
Derivados de glucagónInfo
- Publication number
- CO2017006308A2 CO2017006308A2 CONC2017/0006308A CO2017006308A CO2017006308A2 CO 2017006308 A2 CO2017006308 A2 CO 2017006308A2 CO 2017006308 A CO2017006308 A CO 2017006308A CO 2017006308 A2 CO2017006308 A2 CO 2017006308A2
- Authority
- CO
- Colombia
- Prior art keywords
- glucagon
- present
- hypoglycemia
- prevention
- treatment
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 5
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 | ||
| PCT/KR2015/014422 WO2016108586A1 (ko) | 2014-12-30 | 2015-12-30 | 안정성이 증가된 글루카곤 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017006308A2 true CO2017006308A2 (es) | 2017-09-29 |
Family
ID=56284642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0006308A CO2017006308A2 (es) | 2014-12-30 | 2017-06-27 | Derivados de glucagón |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (enExample) |
| EP (2) | EP3575314B1 (enExample) |
| JP (2) | JP6797122B2 (enExample) |
| KR (1) | KR102291020B1 (enExample) |
| CN (1) | CN107636009B (enExample) |
| AR (1) | AR103322A1 (enExample) |
| AU (1) | AU2015372818A1 (enExample) |
| CL (1) | CL2017001718A1 (enExample) |
| CO (1) | CO2017006308A2 (enExample) |
| CR (1) | CR20170293A (enExample) |
| DO (1) | DOP2017000156A (enExample) |
| EA (1) | EA035527B1 (enExample) |
| EC (1) | ECSP17040923A (enExample) |
| ES (1) | ES2976562T3 (enExample) |
| GT (1) | GT201700150A (enExample) |
| HK (1) | HK1248713A1 (enExample) |
| IL (2) | IL253206B (enExample) |
| MA (1) | MA40709B1 (enExample) |
| MX (1) | MX2017008569A (enExample) |
| MY (1) | MY185334A (enExample) |
| PE (2) | PE20171154A1 (enExample) |
| PH (1) | PH12017501222B1 (enExample) |
| SG (1) | SG11201705376SA (enExample) |
| TN (1) | TN2017000271A1 (enExample) |
| TW (1) | TW201639878A (enExample) |
| UA (1) | UA126960C2 (enExample) |
| WO (1) | WO2016108586A1 (enExample) |
| ZA (1) | ZA201705015B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015372818A1 (en) | 2014-12-30 | 2017-07-27 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| PE20240215A1 (es) | 2015-06-30 | 2024-02-16 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CN115920077B (zh) | 2015-12-31 | 2025-07-04 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
| UA126662C2 (uk) | 2016-06-29 | 2023-01-11 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування |
| WO2018143729A1 (ko) | 2017-02-03 | 2018-08-09 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
| SG11202005510SA (en) * | 2017-12-22 | 2020-07-29 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having a novel structure and use thereof |
| EP3743097A1 (en) * | 2018-01-23 | 2020-12-02 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| MX2021007124A (es) * | 2018-12-21 | 2021-08-11 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que incluye insulina y glucagon. |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| US20230192800A1 (en) | 2020-05-22 | 2023-06-22 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glucagon derivative |
| EP4183407A4 (en) * | 2020-07-15 | 2024-08-14 | Hanmi Pharm. Co., Ltd. | THERAPEUTIC USE OF A GLUCAGNONE DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASES |
| IL305549A (en) | 2021-04-09 | 2023-10-01 | Hanmi Pharm Ind Co Ltd | Pharmaceutical composition for the prevention or treatment of chronic kidney disease including a glucagon derivative |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115490760B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| CA2455963C (en) | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
| PT1605897E (pt) | 2003-03-19 | 2012-09-10 | Lilly Co Eli | Compostos de glp-1 ligado a polietilenoglicol |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| RU2352583C2 (ru) | 2003-11-13 | 2009-04-20 | Ханми Фарм. Инд. Ко., Лтд. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ |
| ES2495741T3 (es) | 2006-04-20 | 2014-09-17 | Amgen, Inc | Compuestos de GLP-1 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| RU2477286C2 (ru) * | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EA017849B1 (ru) | 2007-02-15 | 2013-03-29 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соагонисты глюкагоновых/glp-1-рецепторов |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| DK2172479T3 (en) | 2007-06-19 | 2016-12-19 | Glytech Inc | GLP-1 peptide having the sugar chain attached thereto |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| CN101983066B (zh) | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| CN104447980A (zh) | 2008-06-17 | 2015-03-25 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| RS53987B1 (sr) | 2009-07-13 | 2015-10-30 | Zealand Pharma A/S | Analozi acilovanog glukagona |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| KR20120128129A (ko) | 2010-01-20 | 2012-11-26 | 질랜드 파마 에이/에스 | 심장 병태의 치료 |
| JP6054861B2 (ja) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| ES2713952T3 (es) | 2010-12-22 | 2019-05-24 | Univ Indiana Res & Tech Corp | Análogos de glucagón que muestran actividad de receptor de GIP |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| WO2012158965A2 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| DK2718318T3 (en) | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these |
| AR086969A1 (es) * | 2011-06-17 | 2014-02-05 | Hanmi Science Co Ltd | Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| HUE039267T2 (hu) | 2012-06-21 | 2018-12-28 | Univ Indiana Res & Tech Corp | GIP-receptor aktivitást mutató glukagon-analógok |
| US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PH12018501454A1 (en) | 2012-11-06 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment |
| WO2014081864A1 (en) | 2012-11-20 | 2014-05-30 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
| KR20160021758A (ko) * | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
| HK1226084A1 (zh) | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| ES2822994T3 (es) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| AU2015372818A1 (en) | 2014-12-30 | 2017-07-27 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| PE20240215A1 (es) * | 2015-06-30 | 2024-02-16 | Hanmi Pharmaceutical Co Ltd | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| CN115920077B (zh) | 2015-12-31 | 2025-07-04 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
-
2015
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 PH PH1/2017/501222A patent/PH12017501222B1/en unknown
- 2015-12-30 HK HK18104685.2A patent/HK1248713A1/en unknown
- 2015-12-30 ES ES19172184T patent/ES2976562T3/es active Active
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko not_active Ceased
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active Active
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017006308A2 (es) | Derivados de glucagón | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| UA118558C2 (uk) | Пептидна сполука | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CR20160367A (es) | Compuesto heterocíclico fusionado | |
| CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| DOP2016000233A (es) | MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B | |
| GT201500293A (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| AR128158A2 (es) | Compuesto heterocíclico | |
| UY35774A (es) | Compuesto heterocíclico | |
| MX381944B (es) | Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| PH12017501205A1 (en) | Glucagon derivatives | |
| AR082278A1 (es) | Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (iii) | |
| CO2017004785A2 (es) | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a | |
| CL2017001680A1 (es) | Composición farmacéutica para el tratamiento de enfermedades gastrointestinales | |
| MX2018004779A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
| CL2022002644A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2022002646A1 (es) | Derivados de glucagón con estabilidad mejorada |